comprehensive -WSS

comprehensive

author：focus 2025-10-01 11:36:31 - browse：45

Feng Zhang Editas — Aera was formed to pursue a nanoparticle described by Feng Zhang in 2021. Susan Walsh/AP

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve one of the biggest bottlenecks in genetic medicine, has laid off a quarter of its staff, the company confirmed to STAT.

The layoffs come as the biotech market remains mired in a now nearly three-year-long downturn that has left startups struggling to attract both private and public funds. Aera attributed the layoffs to those headwinds and indicated it had axed a portion of the company dedicated to developing new gene-editing enzymes.

“In 2023, Aera launched to pursue an ambitious mission to develop transformative genetic medicines by harnessing enabling delivery technologies and precision payloads,” spokesman Dan Budwick said in a statement. “Although Aera remains in a strong cash position today, given the current biotech funding environment, we have chosen to take steps to focus our strategy and investments on the development of our novel delivery platforms, thereby further extending our cash runway.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Addressing health care workers' trauma can help fight burnout

WSS

Scrutiny of post

Digital health: a case of mistaken identity

Dark money group runs ads on China biotech bill

Listen: More tumult at BIO & coercive care for sickle cell patients

Insmed lung disease drug hits target in key Phase 3 trial

Report: NIH

knowledge

comprehensive

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

First Opinion Podcast: What happens when kids become caregivers?

Medicare details structure of new drug price negotiation program

Dark money group runs ads on China biotech bill

The high cost of giving birth even with insurance

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

23andMe had bad news about my health. I wish a person had delivered it

Questions and answers about ramping up H5N1 bird flu vaccine

Hepatitis C has a cure — but many Americans still lack access to it

Investigation reveals sickle cell patients pressured into sterilizations

explore

Citing H5N1 threat, CDC urges peak flu monitoring this summer

H5N1 bird flu outbreak: Second human case reported, in Michigan

Dark money group runs ads on China biotech bill

Biogen joins immunology wave with $1.15 billion acquisition of HI

Akili, maker of video game for ADHD, to be acquired for 34 million

Scrutiny of post

hotspot

focus

entertainment

knowledge